AtriCure (NASDAQ:ATRC) Hits New 52-Week High – Still a Buy?

Shares of AtriCure, Inc. (NASDAQ:ATRC) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $43.18 and last traded at $42.9250, with a volume of 363599 shares trading hands. The stock had previously closed at $41.64.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on ATRC shares. UBS Group reduced their price target on AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, July 28th. Canaccord Genuity Group lifted their price objective on shares of AtriCure from $53.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Wall Street Zen cut shares of AtriCure from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 2nd. Zacks Research upgraded shares of AtriCure from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 24th. Finally, Weiss Ratings raised shares of AtriCure from a “sell (e+)” rating to a “sell (d+)” rating in a report on Tuesday, July 28th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $48.50.

AtriCure Trading Up 3.1%

The business has a 50 day simple moving average of $32.56 and a two-hundred day simple moving average of $31.35. The company has a current ratio of 4.22, a quick ratio of 3.19 and a debt-to-equity ratio of 0.14. The stock has a market cap of $2.18 billion, a price-to-earnings ratio of 204.53 and a beta of 1.20.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. The company had revenue of $153.60 million for the quarter, compared to the consensus estimate of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same period in the previous year, the business earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, equities analysts anticipate that AtriCure, Inc. will post 0.2 EPS for the current year.

Insider Activity

In other AtriCure news, Director Sven Wehrwein sold 25,000 shares of the firm’s stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $37.84, for a total transaction of $946,000.00. Following the completion of the transaction, the director directly owned 40,518 shares of the company’s stock, valued at $1,533,201.12. This trade represents a 38.16% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Karen Prange sold 3,564 shares of the business’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $38.80, for a total transaction of $138,283.20. Following the completion of the sale, the director directly owned 22,809 shares of the company’s stock, valued at $884,989.20. The trade was a 13.51% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 47,246 shares of company stock worth $1,777,845 over the last ninety days. Insiders own 4.00% of the company’s stock.

Institutional Investors Weigh In On AtriCure

Institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in AtriCure by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 4,903,755 shares of the medical device company’s stock worth $193,993,000 after purchasing an additional 62,861 shares during the last quarter. BlackRock Inc. bought a new stake in AtriCure during the second quarter valued at $125,198,000. Wellington Management Group LLP raised its holdings in shares of AtriCure by 8.1% during the third quarter. Wellington Management Group LLP now owns 4,292,087 shares of the medical device company’s stock worth $151,296,000 after purchasing an additional 322,818 shares during the period. First Light Asset Management LLC raised its holdings in shares of AtriCure by 32.0% during the fourth quarter. First Light Asset Management LLC now owns 1,175,445 shares of the medical device company’s stock worth $46,501,000 after purchasing an additional 285,083 shares during the period. Finally, Dimensional Fund Advisors LP lifted its position in shares of AtriCure by 8.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 997,759 shares of the medical device company’s stock worth $28,466,000 after buying an additional 75,862 shares during the last quarter. 99.11% of the stock is currently owned by institutional investors.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.